Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab with CHOP in First-Line PTCL
NCT00441025Phase 2Terminated
- Sponsor
- Mahidol University
- Start
- Sep 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in peripheral T-cell lymphoma (PTCL), sponsored by Mahidol University. Primary endpoints: Objective Response Rate, Progression-Free Survival and 1 more. Started Sep 2006; status: terminated.
02
Drugs
alemtuzumab
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT00441025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00441025.